IMRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.312

-46.26%

-0.350

-16.67%

-0.370

-7.5%

Estimates Revision

The market is revising No Change the revenue expectations for Immuneering Corporation (IMRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -24.06%.

EPS Estimates for FY2025

Revise Downward

-11.57%

In Past 3 Month

Stock Price

Go Down

-24.06%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

11.00

Averages

17.60

High

30.00

Current: 0.000

Low

11.00

Averages

17.60

High

30.00

Leerink

Outperform

maintain

$NULL

2026-01-08

New

Reason

Leerink

Price Target

$NULL

2026-01-08

New

maintain

Outperform

Reason

After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, Leerink says the updated 12 month data highlights "impressive" 64% landmark OS, which the analyst calls "encouraging." The median progression free survival deteriorated to 8.5 months, which the analyst notes is similar to the 8.5 months shown by Revolution Medicines' (RVMD) daraxonrasib in second-line PDAC, but adds that Immuneering may have a safety advantage that "could facilitate a niche in frailer patients." Leerink has a Outperform rating on Immuneering shares, which are down $3.37, or 40%, to $4.96 in afternoon trading.

Leerink

Outperform

initiated

$15

2025-10-31

Reason

Leerink

Price Target

$15

2025-10-31

initiated

Outperform

Reason

Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.

Mizuho

NULL -> Outperform

maintain

$10 -> $12

2025-10-29

Reason

Mizuho

Price Target

$10 -> $12

2025-10-29

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Immuneering to $12 from $10 and keeps an Outperform rating on the shares.

Oppenheimer

Jay Olson

Outperform

maintain

$21 -> $30

2025-09-25

Reason

Oppenheimer

Jay Olson

Price Target

$21 -> $30

2025-09-25

maintain

Outperform

Reason

Oppenheimer analyst Jay Olson raised the firm's price target on Immuneering to $30 from $21 and keeps an Outperform rating on the shares after the company surprised with an earlier-than-expected update on atebimetinib in 1L PDAC. The firm says that \"the sooner the better when data are this strong,\" exceeding expectations that it had recently laid out. Encouragingly, the 9-month overall survival rate, a key focus of the update, achieved 86%, well above Oppenheimer's 75% expectation and clearly separated from historical GnP benchmarks. The favorable OS outcome was further supported by an impressive 53% PFS rate at 9 months, which altogether reinforces the efficacy contribution of atebimetinib on top of mGnP. Moreover, atebimetinib+mGnP continued to demonstrate a favorable tolerability profile, the firm adds.

Mizuho

NULL

Outperform

maintain

$8 -> $10

2025-06-19

Reason

Mizuho

Price Target

$8 -> $10

2025-06-19

maintain

NULL

Outperform

Reason

Mizuho raised the firm's price target on Immuneering to $10 from $8 and keeps an Outperform rating on the shares. The company announced positive updated Phase 2a data for lead asset IMM-1-104 in first-line pancreatic cancer in combination with modified Gemcitabine, a standard-of-care treatment, the analyst tells investors in a research note. The firm came away "very impressed" by this first look at the overall survival and progression-free survival data.

Needham

Ami Fadia

Strong Buy

Reiterates

$12

2025-04-10

Reason

Needham

Ami Fadia

Price Target

$12

2025-04-10

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Immuneering Corp (IMRX.O) is -4.66, compared to its 5-year average forward P/E of -3.93. For a more detailed relative valuation and DCF analysis to assess Immuneering Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.93

Current PE

-4.66

Overvalued PE

-0.38

Undervalued PE

-7.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.97

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.74

Undervalued EV/EBITDA

-5.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

288.67

Current PS

0.00

Overvalued PS

1089.61

Undervalued PS

-512.26

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IMRX News & Events

Events Timeline

No data

News

4.5

14:03 PMBenzinga

U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%

4.0

01-08Benzinga

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction

9.5

01-08Benzinga

Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026

People Also Watch

Frequently Asked Questions

What is Immuneering Corp (IMRX) stock price today?

The current price of IMRX is 4.655 USD — it has decreased -1.59 % in the last trading day.

What is Immuneering Corp (IMRX)'s business?

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

What is the price predicton of IMRX Stock?

What is Immuneering Corp (IMRX)'s revenue for the last quarter?

Immuneering Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Immuneering Corp (IMRX)'s earnings per share (EPS) for the last quarter?

Immuneering Corp. EPS for the last quarter amounts to -0.38 USD, decreased -22.45 % YoY.

What changes have occurred in the market's expectations for Immuneering Corp (IMRX)'s fundamentals?

How many employees does Immuneering Corp (IMRX). have?

Immuneering Corp (IMRX) has 66 emplpoyees as of January 10 2026.

What is Immuneering Corp (IMRX) market cap?

Today IMRX has the market capitalization of 300.57M USD.